Drug intelligence / Profile preview

ALM0118

Development stage: Preclinical
Lead developer: Alchemedicine
Modality: Small Molecules
Administration: Intravenous

Overview

ALM0118 is a small molecule angiotensin II type 1 (AT1) receptor antagonist (ARB) currently under development by Alchemedicine. While most ARBs are formulated for oral administration in the chronic management of hypertension, ALM0118 is specifically designed as an injectable formulation for intravenous (IV) use. By blocking the AT1 receptor, the drug inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, thereby lowering blood pressure. It is currently in the preclinical stage of development, potentially targeting clinical scenarios where rapid blood pressure control is required or oral intake is not feasible.

Other names: AT1 antagonistAT-1 antagonistAT 1 antagonistInjectable ARB

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on ALM0118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM0118.

Explore the full profile